Skip to main content
. 2024 Oct 23;146(44):30565–30572. doi: 10.1021/jacs.4c12035

Figure 1.

Figure 1

Schematic representation of receptor-controlled targeting of resistant leukemic B cells using bioorthogonal chemokine ligation. The chemokines CXCL10 and CXCL13 are modified with BODIPY fluorophores or activating groups. Because chemokines are recognized by their cognate receptors (e.g., CXCR3 and CXCR5, respectively), the fluorescent bioorthogonal adduct is only formed in B cells expressing both receptors (i.e., drug-resistant leukemic cells).